Compare IPWR & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPWR | GANX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 76.8M |
| IPO Year | 2013 | 2021 |
| Metric | IPWR | GANX |
|---|---|---|
| Price | $2.76 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 113.8K | ★ 619.8K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | $2,550.55 | N/A |
| Revenue Next Year | $600.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.62 | $1.15 |
| 52 Week High | $9.30 | $4.34 |
| Indicator | IPWR | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 24.56 | 30.94 |
| Support Level | $2.63 | N/A |
| Resistance Level | $3.33 | $2.01 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 6.60 | 21.67 |
Ideal Power Inc is engaged in the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.